autogene cevumeran + atezolizumab + folinic acid + fluorouracil + irinotecan + oxaliplatin

This is a combination drug regimen consisting of: - **autogene cevumeran**, a personalized mRNA-based neoantigen vaccine designed to stimulate an immune response against patient-specific tumor antigens[4] - **atezolizumab**, a monoclonal antibody that targets and inhibits PD-L1, a checkpoint protein on tumor cells[4] - **folinic acid (leucovorin)**, a vitamin used to increase the effectiveness of fluorouracil[5] - **fluorouracil**, a pyrimidine analog and antimetabolite that inhibits thymidylate synthase, impairing DNA synthesis[5] - **irinotecan**, a topoisomerase I inhibitor that induces DNA strand breaks[5] - **oxaliplatin**, a platinum-based chemotherapeutic that forms DNA crosslinks, triggering apoptosis[5] The regimen combines an individualized immunotherapy (autogene cevumeran), a checkpoint inhibitor (atezolizumab), and standard cytotoxic chemotherapy (FOLFIRINOX: folinic acid, fluorouracil, irinotecan, oxaliplatin). Its mechanism aims to induce robust tumor-specific T cell responses, block immune suppression via PD-L1, and directly kill proliferating cancer cells by impairing DNA replication and synthesis[4][5][2].

Brand names

Tecentriq

Other names

autogene cevumeranfolinic acidfluorouracilirinotecanoxaliplatin